Skip to content

Study on the efficacy and mechanism of rTMS in the treatment of melancholic depression via the left prefrontal-precuneus-hippocampal neural circuit

Study on the efficacy and mechanism of rTMS in the treatment of melancholic depression via the left prefrontal-precuneus-hippocampal neural circuit

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067817
Enrollment
Unknown
Registered
2023-01-28
Start date
2023-01-28
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

major depressive disorder with melancholic features

Interventions

HF_rTMS PCU group:high-frequency rTMS
sham :Sham rTMS
HF_rTMS DLPFC group:high-frequency rTMS
healthy control:none

Sponsors

The First Affiliated Hospital of Kunming Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18-60 years, the gender ratio is roughly equal; 2. Diagnosis of MDD was in accordance with the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) (screening by Mini-International Neuropsychiatric Interview (MINI)); 3. First episode or recurrent episode without medication treatment (antidepressants, antipsychotics, mood stabilizers); 4. Chinese Han people, three generations of direct blood relatives are both Han; 5. Primary school graduates or above (years of education >= 6 years) can understand the content of the scale; 6. Score of 17-HDRS >= 17 or MADRS >= 12; 7. Willing to use contraception during the study period and 2 months after the study; 8. After fully understanding the safety of rTMS, they are willing to actively cooperate with treatment and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients who are participating in or have finished other medical studies but cannot be excluded from the continuing impact of the studies; 2. Obvious suicidal ideation, attempt or behavior (e.g., score of item 3 of 17- HDRS >= 3 or BSI-CV >= 6); 3. Serious physical illness (e.g., brain tumor or damage) or condition (e.g., current pregnancy or breastfeeding) that may interfere with the study protocol; 4. Inability to undergo a MRI scan (Such as implantation of heart stents, metal dentures, etc.); 5. IQ < 70 or Suspected mental retardation; 6. With substance abuse or dependence or Urine tested positive for banned drugs during screening.

Design outcomes

Primary

MeasureTime frame
Hamilton depression Scale reduction rate;The reduction rate of the Snaith-Hamilton Pleasure Scale (SHAPS) ;Cranial magnetic resonance;

Secondary

MeasureTime frame
Reduction rate of Pittsburgh sleep quality index (PSQI) scale;Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) scale;

Countries

China

Contacts

Public ContactZonglin Shen

The First Affiliated Hospital of Kunming Medical University

shenzl1987@163.com+86 15198792084

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026